Apoptosis in malignant diseases

Archive of Oncology

Volumn 13, Issue 1, 2005, Pages 19-22

  Brajušković, Goran R ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Apoptosis; Gene Therapy; Neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DACARBAZINE; MX 2060; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; DIABETES MELLITUS; DRUG EFFECT; GENE DELETION; GENE MUTATION; GENE THERAPY; HEPATITIS; HOMEOSTASIS; HUMAN; IMMUNOTHERAPY; LUNG CANCER; LYMPHATIC LEUKEMIA; MELANOMA; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PARKINSON DISEASE; PROSTATE CANCER; TUMOR GROWTH; TUMOR REGRESSION;

EID: 27644493741     PISSN: 03547310     EISSN: None     Source Type: Journal    
DOI: 10.2298/AOO0501019B     Document Type: Article

References (40)

1. Schwartzman RA, Cidlowski JA. Apoptosis: The Biochemistry and Molecular Biology of Programmed Cell Death. Endocrine Reviews 1993;14(2):133-51.
2. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implication in tissue kinetics. Br J Cancer 1972;26:239-57.
3. Stewart BW. Mechanisms of Apoptosis: Integration of Genetic, Biochemical, and Cellular Indicators. J Natl Cancer lnst 1994;86(17):1286-96.
4. Buja LM, Eigenbrodt ML, Eigenbrodt EH. Apoptosis and Necrosis. Basic Types and Mechanisms of Cell Death. Arch Pathol Lab Med 1993;117:1208-13.
5. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95.
6. Los M, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 2003;8(2):67-77.
7. Philchenkov A. Caspases: potentional targets for regulating cell death. J Cell Mol Med 2004;8(4):432-44.
8. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacology & Therapeutics 2001;92:57-70.
9. Kolenko VM, Uzzo RG, Bukowski R, Finke JH.Caspase-dependent and -independent death pathways in cancer therapy. Apoptosis 2000;5(1):17-20.
10. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
11. Antonsson B. Bax and other pro-apoptotic Bcl-2 family "killer - proteins" and their victim, the mitochondria. Cell Tissue Res 2001;306:347-61.
12. . Mullauer L, Gruber P, Sebinger D, Buch J, Wohlfart S, Chott A. Mutation in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 2001;488:211-31.
13. Green DR, Reed JC. Mitochondria and Apoptosis. Science 1989:281:1309-12.
14. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15(22):2922-33.
15. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends in Cell Biology 2000;10:369-77.
16. van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P. The role of mito-chondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 2002;9(10):1031-42.
17. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB. Bcl-2 inhibits Sax translo-cation from cytosol to mitochondria during drug - induced apoptosis of human tumor cells. Cell Death and Differentiation 2000;7:102-111.
18. Watson AJM. Apoptosis and Colorectal Cancer. Gut 2004;53:1701-9.
19. Korsmeyer SJ. Bcl-2 Gene Family and Regulation of Programmed Cell Death. Cancer Res 1999;159:16935-17005.
20. Shen Y, White E. p-53 - dependent apoptotic pathways. Adv Cancer Res 2001;82:55-84.
21. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
22. McGill G, Fisher DE. Apoptosis in tumorigenesis and cancer therapy. Frontiers in Biosciences 1997;2:d353-379.
23. Wohlfart S, Sebinger D, Gruber P, Buch J, Polgar D, Krupitza G et al. FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am J Pathol 2004;164(3):1081-9.
24. Nagasawa T, Takakuwa T, Takayama H, Dong Z, Miyagawa S, Itami S et al. Fas gene mutations in mycosis fungoides: analysis of laser capture- microdissected specimens from cutaneous lesions. Oncology 2004;67(2):130-4.
25. Landowski TH, Qu I, Buyuksal I, Oainter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997;90:4266-70.
26. Voutsadakis IA. Apoptosis and the pathogenesis of lymphoma. Acta Oncol 2000;39(2):151-6.
27. Cook JR, Craig FE, Swerdlow SH. Bcl-2 expression by multicolor flow cytometric analysis in the diagnosis of follicular lymphoma in lymph node and bone marrow. Am J Clin Pathol 2003;119(1):145-51.
28. Schriever F, Huhn D. New directions in the diagnosis and treatment of chronic lymphocytic leukemia. Drugs 2003;63(10):953-69.
29. Schimmer AD, Munk-Pedrsen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 2003;4(3):211-8.
30. Bykov VJ, Wiman KG. Novel cancer therapy by reactivation of the p53 apoptotic pathway. Ann Medd 2003;35(7):458-65.
31. Lynch JW. Programmed cell death. Cancer Res Therapy and Control 1993;3:213-9.
32. Debatin KM, Stanhnke K, Fulda S. Apoptosis in hematological disorders. Semin Cancer Biol 2003;13(2):149-58.
33. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994;78:539-42.
34. Desoize B. Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 1994;14:2291-4.
35. Fang B, Roth JA. Tumor-suppressing gene therapy. Cancer Biol Ther 2003;4Suppl 1:5115-21.
36. Meng RD, El Deiry W. Clinical Applications of Tumor-Suppressor Gene Therapy. In: Lattime EC, Gerson SL, editors. Gene Therapy of Cancer. 2nd ed. San Diego: Academic Press; 2002. p. 273-8.
37. Meng RD, El Deiry W. Cancer Gene Therapy with Tumor Suppressor Genes Involved in Cell - Cycle Control. In: Lattime EC, Gerson SL, editors. Gene Therapy of Cancer. 2nd ed. San Diego: Academic Press; 2002. p. 279-97.
38. Makin G. Targeting apoptosis in cancer chemotherapy. Expert Opin Ther Targets 2002;6(1):73-84.
39. Los Marek, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discovery Today 2003;8(2):67-77.
40. Lebedeva IV, Stein CA. Antisense Downregulation of the Apoptosis - Related Bcl-2 and Bcl-xl Proteins: A new Approach to Cancer Therapy. In: Lattime EC, Gerson SL, editors. Gene Therapy of Cancer. 2nd ed. San Diego: Academic Press; 2002. p. 315-30.